EDITORIAL article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1649258
This article is part of the Research TopicPharmacogenomics for Improving Drug Safety and Efficacy in CancerView all 9 articles
Editorial: Pharmacogenomics for Improving Drug Safety and Efficacy in Cancer
Provisionally accepted
- 1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Research Center for Drug Precision Industrial Technology, Sichuan University West China School of Pharmacy, Chengdu, China
- 2Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
- 3Mental Health Center, West China Hospital, Sichuan University, Chengdu, China
- 4Department of Pathology, Xiangya Hospital, Central South University, Changsa, China
- 5College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia
- 6Department Clinical Neurophysiology, Centre for the Research and Rehabilitation of Hereditary Ataxias, Holguín, Cuba
- 7Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The advancement of precision oncology has gradually reshaped cancer treatment paradigms, with pharmacogenomics emerging as a potentially valuable component of therapeutic approach (Hu et al., 2024;Jin et al., 2023;Mondello et al., 2024). By identifying genetic variations that may influence drug response and toxicity, pharmacogenomic research aims to support more tailored therapeutic strategies, potentially enhancing efficacy while reducing adverse effects (Li et al., 2024;Qahwaji et al., 2024;Shriver et al., 2024). This research topic was developed to examine current progress in translating pharmacogenomic knowledge into clinical applications that could optimize drug selection, mitigate toxicity, and address resistance in cancer therapy.Understanding underlying mechanisms remains essential for many pharmacogenomic insights (Chen et al., 2017). Casotti et al. explored methotrexate (MTX) resistance in high-grade osteosarcoma through a multimodal targeted next-generation sequencing approach (https://doi.org/10.3389/fphar.2023.1294873).Their identification of single nucleotide polymorphisms (SNPs) in the folate pathway and transporter genes, alongside a novel DHFR-MSH3 fusion transcript, provided initial evidence on genomic and transcriptomic factors potentially contributing to MTX resistance. These findings provide candidate biomarkers for prediction of drug resistance and possible therapeutic targets, underscoring the need for further functional studies to clarify the impact of genetic alterations beyond the DNA sequence.In pediatric oncology, individualized dosing remains critical due to developmental variability in drug metabolism (Vander Schaaf, et al. 2024) The practical relevance of pharmacogenomics in real-world settings is illustrated by case reports included in this collection.
Keywords: pharmacogenomics, drug safety, precision oncology, cancer pharmacotherapy, genetic variability
Received: 18 Jun 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 He, Fu, Xu, Alshargi, Rodríguez-Labrada and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhi-Yao He, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Research Center for Drug Precision Industrial Technology, Sichuan University West China School of Pharmacy, Chengdu, China
Xiao-bo Zhong, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.